14 Perspectives of Aptamers for Medical Applications
443
Table 14.4
Aptamers in clinical trials
Molecular
target
Aptamer
Sponsor
Medical indications
Current status
Duration
FDA
approved
VWF
ARC1779
Archemix Corp
von Willebrand Factor
related platelet
disorders
Phase2, completed
2008-2009
No
Factor Ixa
REG1
National Heart, Lung, and
Blood Institute (NHLBI)
National Institutes of
Health Clinical Center
(CC)
Safety and Dosing
Evaluation of REG1
Anticoagulation
System in Healthy
Phase1, completed
2005
No
Regado Biosciences, Inc
Safety, Tolerability
and PK/PD in healthy
volunteer
Phase1, completed
2009
No
Regado Biosciences, Inc
Coronary Artery
Disease
Phase2, completed
2007-2008/2009-2011 No
Factor Ixa
Aptamer-RNA Target
to Factor IXa
NHLBI
acute coronary
syndromes
Phase1, completed
2005
No
Complement
factor C5
ARC1905 (ANTI-C5
APTAMER)
Ophthotech Corporation
Neovascular
Age-Related Macular
Degeneration
Phase1, completed
2009-2017
No
Zimura®(avacincaptad
pego
Ophthotech Corporation
Macular Degeneration Phase2, completed
2019
yes
CCL2
NOX-E36
NOXXON Pharma AG
Solid tumor
Phase1/2, completed
2009
No
CXCL12
NOX-A12(Olaptesed
pegol)
NOXXON Pharma AG
Solid tumor;Chronic
Lymphocytic
Leukemia
Multiple Myeloma;
Phase1/2, completed
2010-2020
No
(continued)